Intellia Therapeutics (NASDAQ:NTLA) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald restated their overweight rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a research note published on Monday morning, Benzinga reports. The firm currently has a $65.00 price objective on the stock. Several other research firms have also commented on NTLA. BMO Capital Markets raised their price target on shares of […]
More Stories
Apple Business Manager: Login Process, Features, Pricing, and More
Apple Business Manager is a free web-based portal that helps businesses to manage, or you can say organize, different Apple...
Hawaii’s Big Island Prepares as Lala Strengthens to Hurricane Ahead of Possible Landfall
By Jeremy Lott Tropical Storm Lala has strengthened to a hurricane and could be the first to make landfall over...
US Tells EU ‘Now It’s Time to Deliver’ on Trade Commitments
By Bill Pan The United States is urging the European Union to further ease its corporate environmental rules, citing commitments...
Iran Accuses Qatar of Holding 3 of Its Military Pilots Captive
By Ryan Morgan The Iranian military, on Aug. 15, claimed three of its pilots are currently being held by Qatar,...
US Mortgage Rates Fall for First Time in 6 Weeks
By Naveen Athrappully The weekly average rate on a 30-year fixed-rate mortgage declined for the most recent week, breaking a...
What Battleground Voters Are Saying About Healthcare Affordability
By Lawrence Wilson “Yes, I do have opinions about this,” said Milwaukee resident Addaru Valentine just after voting in Wisconsin’s...